TY - JOUR
T1 - Epilepsy and hypertension
T2 - The possible link for sudden unexpected death in epilepsy?
AU - Szczurkowska, Patrycja J.
AU - Polonis, Katarzyna
AU - Becari, Christiane
AU - Hoffmann, Michał
AU - Narkiewicz, Krzysztof
AU - Chrostowska, Marzena
N1 - Funding Information:
Christiane Becari was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil (FAPESP 2017/21539-7; 2018/23718-8).
Publisher Copyright:
© 2021 Via Medica.
PY - 2021
Y1 - 2021
N2 - Epilepsy affects about 50 million people worldwide. Sudden unexpected death in epilepsy (SUDEP) is the main cause of death in epilepsy accounting for up to 17% of all deaths in epileptic patients, and therefore remains a major public health problem. SUDEP likely arises from a combination and inter-action of multiple risk factors (such as being male, drug resistance, frequent generalized tonic-clonic seizures) making risk prediction and mitigation challenging. While there is a general understanding of the physiopathology of SUDEP, mechanistic hypotheses linking risk factors with a risk of SUDEP are still lacking. Identifying cross-talk between biological systems implicated in SUDEP may facilitate the development of improved models for SUDEP risk assessment, treatment and clinical management. In this review, the aim was to explore an overlap between the pathophysiology of hypertension, cardiovascular disease and epilepsy, and discuss its implication for SUDEP. Presented herein, evidence in literature in support of a cross-talk between the renin–angiotensin system (RAS) and sympathetic nervous system, both known to be involved in the development of hypertension and cardiovascular disease, and as one of the underlying mechanisms of SUDEP. This article also provides a brief description of local RAS in brain neuroinflammation and the role of centrally acting RAS inhibitors in epileptic seizure alleviation.
AB - Epilepsy affects about 50 million people worldwide. Sudden unexpected death in epilepsy (SUDEP) is the main cause of death in epilepsy accounting for up to 17% of all deaths in epileptic patients, and therefore remains a major public health problem. SUDEP likely arises from a combination and inter-action of multiple risk factors (such as being male, drug resistance, frequent generalized tonic-clonic seizures) making risk prediction and mitigation challenging. While there is a general understanding of the physiopathology of SUDEP, mechanistic hypotheses linking risk factors with a risk of SUDEP are still lacking. Identifying cross-talk between biological systems implicated in SUDEP may facilitate the development of improved models for SUDEP risk assessment, treatment and clinical management. In this review, the aim was to explore an overlap between the pathophysiology of hypertension, cardiovascular disease and epilepsy, and discuss its implication for SUDEP. Presented herein, evidence in literature in support of a cross-talk between the renin–angiotensin system (RAS) and sympathetic nervous system, both known to be involved in the development of hypertension and cardiovascular disease, and as one of the underlying mechanisms of SUDEP. This article also provides a brief description of local RAS in brain neuroinflammation and the role of centrally acting RAS inhibitors in epileptic seizure alleviation.
KW - Cardiovascular diseases
KW - Epilepsy
KW - Hypertension
KW - Neuroinflammation
KW - Renin–angiotensin system
KW - SUDEP
UR - http://www.scopus.com/inward/record.url?scp=85088009301&partnerID=8YFLogxK
U2 - 10.5603/CJ.a2019.0095
DO - 10.5603/CJ.a2019.0095
M3 - Article
C2 - 31565791
AN - SCOPUS:85088009301
SN - 1897-5593
VL - 28
SP - 330
EP - 335
JO - Cardiology Journal
JF - Cardiology Journal
IS - 2
ER -